CA2554511C - Chlorite in the treatment of neurodegenerative disease - Google Patents
Chlorite in the treatment of neurodegenerative disease Download PDFInfo
- Publication number
- CA2554511C CA2554511C CA2554511A CA2554511A CA2554511C CA 2554511 C CA2554511 C CA 2554511C CA 2554511 A CA2554511 A CA 2554511A CA 2554511 A CA2554511 A CA 2554511A CA 2554511 C CA2554511 C CA 2554511C
- Authority
- CA
- Canada
- Prior art keywords
- als
- disease
- chlorite
- cells
- macrophage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229910001919 chlorite Inorganic materials 0.000 title claims abstract description 65
- 229910052619 chlorite group Inorganic materials 0.000 title claims abstract description 65
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 title claims description 43
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract description 52
- 230000004770 neurodegeneration Effects 0.000 title abstract description 31
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 234
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 17
- -1 chlorite ions Chemical class 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical group [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 4
- 229960002218 sodium chlorite Drugs 0.000 claims description 4
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 abstract description 201
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 88
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 84
- 210000004369 blood Anatomy 0.000 abstract description 72
- 239000008280 blood Substances 0.000 abstract description 72
- 238000002560 therapeutic procedure Methods 0.000 abstract description 69
- 238000000034 method Methods 0.000 abstract description 33
- 230000007423 decrease Effects 0.000 abstract description 29
- 238000012544 monitoring process Methods 0.000 abstract description 16
- 230000005931 immune cell recruitment Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 116
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 114
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 114
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 109
- 201000010099 disease Diseases 0.000 description 84
- 210000001616 monocyte Anatomy 0.000 description 56
- 102000006354 HLA-DR Antigens Human genes 0.000 description 55
- 108010058597 HLA-DR Antigens Proteins 0.000 description 55
- 208000024891 symptom Diseases 0.000 description 52
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 49
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 49
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 49
- 230000004913 activation Effects 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 44
- 230000002159 abnormal effect Effects 0.000 description 33
- 230000002062 proliferating effect Effects 0.000 description 31
- 230000035755 proliferation Effects 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 239000000523 sample Substances 0.000 description 24
- 206010061818 Disease progression Diseases 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 19
- 230000005750 disease progression Effects 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 18
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 17
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 230000001575 pathological effect Effects 0.000 description 15
- 210000005259 peripheral blood Anatomy 0.000 description 15
- 239000011886 peripheral blood Substances 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- 239000012472 biological sample Substances 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- 210000002161 motor neuron Anatomy 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 12
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 11
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 11
- 208000012902 Nervous system disease Diseases 0.000 description 11
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 11
- 229940047495 celebrex Drugs 0.000 description 11
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 11
- 230000008506 pathogenesis Effects 0.000 description 11
- 229960004181 riluzole Drugs 0.000 description 11
- 210000003169 central nervous system Anatomy 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000006735 deficit Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000006044 T cell activation Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000000750 progressive effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 6
- 208000037357 HIV infectious disease Diseases 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- 230000004186 co-expression Effects 0.000 description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000008092 positive effect Effects 0.000 description 6
- 230000004075 alteration Effects 0.000 description 5
- 230000005934 immune activation Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000002250 progressing effect Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000011225 antiretroviral therapy Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010065040 AIDS dementia complex Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010071299 Slow speech Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940085392 excedrin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000027737 inability to think clearly Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 208000026473 slurred speech Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940087652 vioxx Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- ZAGNMMRDHSEOPE-UHFFFAOYSA-N (2-chlorophenyl) n-methylcarbamate Chemical compound CNC(=O)OC1=CC=CC=C1Cl ZAGNMMRDHSEOPE-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 1
- 206010000807 Acute HIV infection Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 244000249062 Artemisia abrotanum Species 0.000 description 1
- 240000002877 Artemisia absinthium Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003067 perivascular macrophage Anatomy 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000314 poly p-methyl styrene Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000001374 small-angle light scattering Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2838392A CA2838392C (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54157604P | 2004-02-03 | 2004-02-03 | |
| US60/541,576 | 2004-02-03 | ||
| PCT/US2005/002469 WO2005076819A2 (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2838392A Division CA2838392C (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2554511A1 CA2554511A1 (en) | 2005-08-25 |
| CA2554511C true CA2554511C (en) | 2016-01-19 |
Family
ID=34860199
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2554511A Expired - Lifetime CA2554511C (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
| CA2838392A Expired - Lifetime CA2838392C (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2838392A Expired - Lifetime CA2838392C (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7105183B2 (OSRAM) |
| EP (2) | EP1711191B1 (OSRAM) |
| JP (3) | JP5072367B2 (OSRAM) |
| CN (2) | CN102423318B (OSRAM) |
| AU (1) | AU2005213300B2 (OSRAM) |
| CA (2) | CA2554511C (OSRAM) |
| WO (1) | WO2005076819A2 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002343609B2 (en) * | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| WO2006009505A1 (en) * | 2004-07-16 | 2006-01-26 | Gyros Patent Ab | Grading of immune responses |
| AU2006244617B2 (en) | 2005-05-09 | 2013-04-18 | Labrador Diagnostics Llc | Point-of-care fluidic systems and uses thereof |
| DE602006014691D1 (de) * | 2005-08-02 | 2010-07-15 | Xbiotech Inc | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN |
| US8067035B2 (en) | 2005-12-22 | 2011-11-29 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
| AU2013234421B2 (en) * | 2005-12-22 | 2015-08-27 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
| US8741230B2 (en) | 2006-03-24 | 2014-06-03 | Theranos, Inc. | Systems and methods of sample processing and fluid control in a fluidic system |
| US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
| US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
| US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| DK2109623T3 (da) * | 2006-05-22 | 2012-01-30 | Xbiotech Inc | Cancerbehandling med anti-IL-1-antistoffer |
| US20080113391A1 (en) | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
| FR2910811B1 (fr) * | 2007-01-03 | 2009-07-10 | Ass Pour Le Dev De La Biothera | Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments |
| US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
| US8034337B2 (en) * | 2008-05-30 | 2011-10-11 | Xbiotech, Inc. | Interleukin-1α antibodies |
| AU2009291536B2 (en) * | 2008-09-12 | 2012-08-16 | Xbiotech Inc. | Targeting pathogenic monocytes |
| AU2010281524A1 (en) * | 2009-08-06 | 2012-02-23 | Neuraltus Pharmaceuticals, Inc. | Treatment of macrophage-related disorders |
| EP4535370A3 (en) | 2009-10-19 | 2025-06-25 | Labrador Diagnostics LLC | Integrated health data capture and analysis system |
| CA2792471A1 (en) * | 2010-03-10 | 2011-09-15 | Yeda Research And Development Co. Ltd | Cellular blood markers for early diagnosis of als and for als progression |
| WO2011159976A2 (en) | 2010-06-18 | 2011-12-22 | Xbiotech, Inc. | Arthritis treatment |
| SI2605771T1 (sl) * | 2010-08-16 | 2018-09-28 | Allergan, Inc. | Metoda aktivacije regulatornih celic t z agonisti adrenergičnih receptorjev alfa-2b |
| CN103153340A (zh) | 2010-08-23 | 2013-06-12 | 埃克斯生物科技公司 | 对肿瘤疾病的治疗 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| ES2695102T3 (es) | 2011-09-23 | 2019-01-02 | Xbiotech Inc | Tratamiento para la caquexia |
| CN104125826A (zh) | 2011-12-22 | 2014-10-29 | 努沃研究有限责任公司 | 亚氯酸盐或氯酸盐脂质体组合物 |
| SG10201906328RA (en) * | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| AU2015258892A1 (en) * | 2014-05-16 | 2016-11-17 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| WO2017079161A2 (en) * | 2015-11-02 | 2017-05-11 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
| CN110382001A (zh) | 2017-02-16 | 2019-10-25 | 埃克斯生物科技公司 | 化脓性汗腺炎的治疗 |
| CA3233863A1 (en) | 2021-10-04 | 2023-04-13 | Arasteh AZHIR | Treatment methods for als patients |
| JP2025518546A (ja) * | 2022-05-19 | 2025-06-17 | ニューヴィヴォ， インコーポレイテッド | 神経変性疾患のバイオマーカー |
| WO2025014800A2 (en) * | 2023-07-07 | 2025-01-16 | The Regents Of The University Of California | Chlorite uses for stem cells |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3213389A1 (de) * | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten |
| US4576945A (en) * | 1982-10-26 | 1986-03-18 | Sanders Mark E | Hexaalkylmelamine-amino-oxy compounds |
| DE3515745A1 (de) | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
| US5051414A (en) * | 1989-08-03 | 1991-09-24 | Dupont Merck Pharmaceutical Company | Inhibition of HIV and other retroviruses by polyoxoanions |
| DE4208828A1 (de) | 1992-03-19 | 1993-09-23 | Oxo Chemie Gmbh | Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen |
| US6099855A (en) * | 1992-06-25 | 2000-08-08 | Bioxy, Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
| US5855922A (en) * | 1995-12-07 | 1999-01-05 | Bio-Cide International, Inc. | Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders |
| US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
| WO1999017787A2 (en) * | 1997-10-06 | 1999-04-15 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| JP2001078775A (ja) * | 1999-09-14 | 2001-03-27 | Kokuritsu Seishin Shinkei Center | マクロファージ機能調節剤 |
| US20040224306A1 (en) * | 1999-11-30 | 2004-11-11 | Frederich-Wilhelm Kuhne | Evaluating and predicting clinical outcomes by gene expression analysis |
| US6685754B2 (en) | 2001-03-06 | 2004-02-03 | Alchemix Corporation | Method for the production of hydrogen-containing gaseous mixtures |
| AU2002343609B2 (en) | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
-
2005
- 2005-01-24 US US11/042,816 patent/US7105183B2/en not_active Expired - Lifetime
- 2005-01-25 CN CN201110317862.3A patent/CN102423318B/zh not_active Expired - Lifetime
- 2005-01-25 CA CA2554511A patent/CA2554511C/en not_active Expired - Lifetime
- 2005-01-25 CN CN2005800037236A patent/CN101102781B/zh not_active Expired - Lifetime
- 2005-01-25 WO PCT/US2005/002469 patent/WO2005076819A2/en not_active Ceased
- 2005-01-25 EP EP05722556.7A patent/EP1711191B1/en not_active Expired - Lifetime
- 2005-01-25 CA CA2838392A patent/CA2838392C/en not_active Expired - Lifetime
- 2005-01-25 AU AU2005213300A patent/AU2005213300B2/en not_active Expired
- 2005-01-25 EP EP12192303.1A patent/EP2574342B1/en not_active Expired - Lifetime
- 2005-01-25 JP JP2006552151A patent/JP5072367B2/ja not_active Expired - Lifetime
-
2006
- 2006-03-17 US US11/378,987 patent/US8029826B2/en active Active
-
2010
- 2010-10-07 US US12/900,361 patent/US20110053186A1/en not_active Abandoned
-
2011
- 2011-10-25 JP JP2011233850A patent/JP5797083B2/ja not_active Expired - Lifetime
-
2012
- 2012-04-27 US US13/458,954 patent/US9364501B2/en not_active Expired - Lifetime
-
2015
- 2015-06-12 JP JP2015118841A patent/JP2015205901A/ja active Pending
-
2016
- 2016-09-12 US US15/262,981 patent/US20170065634A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005213300A1 (en) | 2005-08-25 |
| CA2838392A1 (en) | 2005-08-25 |
| US20060159775A1 (en) | 2006-07-20 |
| US20170065634A1 (en) | 2017-03-09 |
| US20110053186A1 (en) | 2011-03-03 |
| CN102423318A (zh) | 2012-04-25 |
| US8029826B2 (en) | 2011-10-04 |
| US20050181068A1 (en) | 2005-08-18 |
| AU2005213300B2 (en) | 2011-06-16 |
| CA2554511A1 (en) | 2005-08-25 |
| US20120295296A1 (en) | 2012-11-22 |
| EP2574342B1 (en) | 2018-03-07 |
| CN102423318B (zh) | 2015-09-09 |
| EP1711191A2 (en) | 2006-10-18 |
| EP2574342A1 (en) | 2013-04-03 |
| US7105183B2 (en) | 2006-09-12 |
| JP2012067110A (ja) | 2012-04-05 |
| CN101102781A (zh) | 2008-01-09 |
| EP1711191A4 (en) | 2008-12-17 |
| CN101102781B (zh) | 2012-06-20 |
| JP5797083B2 (ja) | 2015-10-21 |
| WO2005076819A3 (en) | 2006-04-13 |
| CA2838392C (en) | 2017-04-04 |
| JP2015205901A (ja) | 2015-11-19 |
| US9364501B2 (en) | 2016-06-14 |
| EP1711191B1 (en) | 2014-03-19 |
| WO2005076819A2 (en) | 2005-08-25 |
| JP5072367B2 (ja) | 2012-11-14 |
| JP2007520554A (ja) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2554511C (en) | Chlorite in the treatment of neurodegenerative disease | |
| Zhang et al. | Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) | |
| Holmgren et al. | Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30) | |
| Mayeux et al. | Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community‐dwelling elderly persons and their first‐degree relatives | |
| Bennett et al. | A comparison of cyclobenzaprine and placebo in the management of fibrositis | |
| AU2014203207B2 (en) | Chlorite in the treatment of neurodegenerative disease | |
| US20170106017A1 (en) | Methods and compositions for treatment of macrophage-related disorders | |
| Dominguez et al. | Long term outcomes in patients with anti-DPPX autoimmunity | |
| Hartard et al. | Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration | |
| Dore et al. | Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection | |
| Ellis et al. | Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans | |
| Golden | Tourette syndrome: Recent advances | |
| DE69732114T2 (de) | Verfahren zum nachweis von autoimmunkrankheiten | |
| Thevos et al. | A comparison of psychopathology in cocaine and alcohol dependence | |
| DOBKIN et al. | Familial progressive bulbar and spinal muscular atrophy: Juvenile onset and late morbidity with ragged‐red fibers | |
| Haupt et al. | Severity of symptoms and rate of progression in Alzheimer's disease: a comparison of cases with early and late onset | |
| Klose | 3.2 Publikation II: CSF oligoclonal IgG bands are not associated with ALS progression and prognosis | |
| Briggs et al. | Screening depressives for causative medical illness; the example of thyroid function testing: II. Hypothesis testing in ambulatory depressives | |
| Hall | Predicting cognitive decline and dementia in elderly twins from indicators of early life oral health | |
| Finkel | Steps toward optimal use of Alzheimer-specific drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |